A Quick Look at Today's Ratings for ResMed(RMD.US), With a Forecast Between $280 to $280
ResMed Is Maintained at Sector Perform by RBC Capital
Bank of America Securities Sticks to Its Buy Rating for Resmed (RMD)
Needham Maintains ResMed(RMD.US) With Hold Rating
Needham Reaffirms Their Hold Rating on Resmed (RMD)
ResMed Analyst Ratings
Mizuho Securities Maintains ResMed(RMD.US) With Buy Rating, Raises Target Price to $250
Analysts Offer Insights on Healthcare Companies: Enanta Pharmaceuticals (ENTA) and Resmed (RMD)
Baird Maintains ResMed(RMD.US) With Buy Rating, Maintains Target Price $280
BofA Securities Maintains ResMed(RMD.US) With Buy Rating, Announces Target Price $270
Resmed Poised for Growth Amid Rising OSA Diagnosis and Market Opportunity: Buy Rating Reaffirmed With Increased Price Objective
ResMed Analyst Ratings
Baird Initiates Coverage On ResMed With Outperform Rating, Announces Price Target of $280
Baird Initiates ResMed(RMD.US) With Buy Rating, Announces Target Price $280
Needham Maintains ResMed(RMD.US) With Hold Rating
Resmed (RMD) Receives a Hold From Needham
ResMed Analyst Ratings
Wolfe Research Downgrades ResMed(RMD.US) to Sell Rating, Announces Target Price $180
Wolfe Research Downgrades ResMed to Underperform From Peer Perform, Price Target Is $180
ResMed Faces Market Disruption and Limited Growth: A Sell Rating Analysis